Quarterly report · Q2
3349.TEDINET S100PZ0K
Period2022-06-01 → 2022-11-30
Filed2023-01-16
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥404.0bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥755.4bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥371.1bn | 2021-06-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | ¥15.4bn | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥15.0bn | 2021-06-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | ¥16.9bn | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥32.9bn | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.5bn | 2021-06-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥16.8bn | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥16.6bn | 2021-06-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.3bn | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥23.2bn | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.2bn | 2021-06-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.3bn | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥11.2bn | 2021-06-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥378.9bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥363.1bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥346.1bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥178.7bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥172.5bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥200.2bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥190.5bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥180.1bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥29.7bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥37.4bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥29.7bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.4bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥41.5bn | at 2021-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥55.1bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥16.8bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.2bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.1bn | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥21.3bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥43.7bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.4bn | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.2bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.2bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.3bn | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥285.34 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.66 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥584.76 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥283.99 | 2021-06-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥126.31 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 52.8% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.5% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.0% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 436
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | Prior1YTDDuration | -17371000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -21295000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -743000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -737000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -1000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -0 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -870000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -918000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -1682000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -1583000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -3297000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -3240000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -13599000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -7688000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 55108000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 37362000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 41508000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 29674000000 | JPY |
| Salaries and bonuses sga | Prior1YTDDuration | 26913000000 | JPY |
| Salaries and bonuses sga | CurrentYTDDuration | 29509000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 130000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 138000000 | JPY |
| Rents sga | Prior1YTDDuration | 9237000000 | JPY |
| Rents sga | CurrentYTDDuration | 10162000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)福岡財務支局長 | |
| Filing date cover page | FilingDateInstant | 2023-01-16 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第41期第２四半期(自 2022年９月１日 至 2022年11月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社コスモス薬品 | |
| Company name in english cover page | FilingDateInstant | COSMOS Pharmaceutical Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 横山 英昭 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)福岡県福岡市博多区博多駅東二丁目10番１号第一福岡ビルＳ館４階 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)092－433－0660（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営企画部長 柴田 太 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)福岡県福岡市博多区博多駅東二丁目10番１号第一福岡ビルＳ館４階 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)092－433－0660（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営企画部長 柴田 太 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E03446 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 33490 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社コスモス薬品 | |
| Filer name in english | FilingDateInstant | COSMOS Pharmaceutical Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |